How AI helps scientists design the next generation of medicines
Designing and developing a new medicine is an expensive, failure-prone scientific challenge. A new drug can take many years to develop, at the cost of a significant investment. And even then, most possible candidates never reach the patient. For biologic medicines, therapies made from engineered proteins rather than synthetic chemistry (which are often used to…
Record details
Published: 23 July 2026
Source: MIT Technology Review
Category: News
Topics: Healthcare · Finance, VC & PE · Biotech
Retrieved: 25 July 2026
Related evidence
These records share source-supplied organisations, an exact publisher byline, automatic topics or regions. The reason is shown on every link; related does not mean supporting, agreeing with or verifying this record.
Closing the data loop in AI-driven drug discovery
MIT Technology Review · 27 July 2026
The path to artificial superintelligence
MIT Technology Review · 27 July 2026
Exclusive: A couple paid more than $800,000 for a gene-editing therapy for their daughter. She died, and it wasn’t made public
Retraction Watch · 23 July 2026
Investors bet on AI drug discovery despite approval gap
Financial Times Technology (headlines) · 21 July 2026
An OpenAI researcher is leaving to build a $2bn AI drug startup that has no name yet
The Next Web AI · 15 July 2026
OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B
TechCrunch · 15 July 2026
How to cite this record
ethics.ai (23 July 2026), “How AI helps scientists design the next generation of medicines,” evidence record 13003, https://ethics.ai/record/13003 (originally published by MIT Technology Review).
Use and limitations
This page is a stable index and citation surface for a source record. ethics.ai did not author the underlying report and has not independently verified every claim. Automatic topics may be imperfect. For consequential use, quote and cite the original publisher.